<DOC>
	<DOCNO>NCT01428297</DOCNO>
	<brief_summary>The study divide 3 part , start safety assessment BPR277 ointment Healthy volunteer ( Part 1 ) . If find well tolerated Part 1 , BPR277 ointment assess two different patient group evaluate safety efficacy atopic dermatitis ( Part 2 ) Netherton syndrome ( Part 3 ) .</brief_summary>
	<brief_title>A Study Evaluating Safety Efficacy Topical BPR277 Treatment Atopic Dermatitis Netherton Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Netherton Syndrome</mesh_term>
	<criteria>Part 1 Healthy volunteer Healthy male female subject non childbearing potential , 18 65 year age inclusive good health Part 2 Patients atopic dermatitis : Male female subject , 18 65 year age inclusive pass screening examination Presence atopic dermatitis confirm Itchy skin condition past 12 month ( must ) Plus three following : 1 . History involvement skin crease 2 . Personal history asthma hay fever 3 . History generally dry skin past year 4 . Onset age 2 year 5 . Visible flexural dermatitis Diagnosis least moderate atopic dermatitis IGA minimum target area ( right left ) situate forearm include antecubital fossa correspond baseline total lesional sign score ( TLSS ) Part 3 Patients Netherton Syndrome : Patients Netherton syndrome , male female subject , 18 65 year age inclusive pass screening examination Confirmed diagnosis Netherton syndrome ( SPINK5 mutation LEKTI deficiency skin ) . Minimum total lesional sign score NS ( TLSSNS ) 59 two select target area baseline . The TLSSNS value need similar two area baseline . Part 1 Healthy volunteer : History hypersensitivity study drug drug similar chemical class history serious allergic reaction . Use prescription drug , herbal supplement , within four ( 4 ) week prior initial dosing , and/or overthecounter ( OTC ) medication , dietary supplement ( vitamin include ) within two ( 2 ) week prior initial dosing . Part 2 Patients atopic dermatitis : History hypersensitivity study drug drug similar chemical class history serious allergic reaction . History abnormal skin reactivity UV light . Unusual exposure UV light previous 3 week study start ( screen ) , include tan sun bed . Pregnant nursing ( lactate ) woman . Women childbearing potential must use highly effective contraception ( define study protocol ) Use topical prescription treatment eczema within 1 week prior initial dose topical corticosteroid ( TCS ) . Recent previous treatment systemic treatment include phototherapy . A washout period require patient eligible participate trial . Part 3 Patients Netherton Syndrome : History hypersensitivity study drug drug similar chemical class history serious allergic reaction . History abnormal skin reactivity UV light . Unusual exposure UV light previous 3 week study start ( screen ) , include tan sun bed . Pregnant nursing ( lactate ) woman . Women childbearing potential must use highly effective contraception ( define study protocol ) Use topical prescription treatment within 2 week prior initial dose study drug . Recent previous treatment systemic treatment . A washout period require patient eligible participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Atopic dermatitis</keyword>
	<keyword>Eczema</keyword>
	<keyword>Skin Diseases , Eczematous</keyword>
	<keyword>Netherton syndrome</keyword>
	<keyword>Skin Diseases , Genetic</keyword>
	<keyword>BPR277</keyword>
</DOC>